GlassScriptPhysician profile
Katie Roedl
NPI 1457743338
$773.90
in general payments reported to CMS, 2019-2025
20 companies · $445 in 2025
The $445 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $62.84 · 2022: $18.77 · 2023: $41.57 · 2024: $206 · 2025: $445.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $692.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $692.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $122.58 | 2025 | Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $87.75 | 2024-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Medtronic, INC. | $62.84 | 2021 | |
| Amgen INC. | $46.32 | 2025 | Otezla, Repatha |
| Merck Sharp & Dohme LLC | $44.51 | 2024-2025 | Vaxneuvance, Capvaxive, Rotateq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.13 | 2025 | Jardiance |
| Pfizer INC. | $41.48 | 2024-2025 | |
| Abbvie INC. | $39.85 | 2024 | |
| Sanofi Pasteur INC. | $35.77 | 2022-2025 | |
| Radius Health, INC. | $34.37 | 2024-2025 | Tymlos |
| Astrazeneca Pharmaceuticals LP | $31.94 | 2025 | Farxiga |
| Exact Sciences Corporation | $27.28 | 2025 | Cologuard Collection Kit |
| Mylan Specialty L.P. | $24.17 | 2024 | Yupelri |
| Viatris Specialty LLC | $23.90 | 2025 | Yupelri |
| Xeris Pharmaceuticals, INC. | $21.69 | 2024 | Keveyis |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $21.15 | 2023 | Jornay Pm |
| Novartis Pharmaceuticals Corporation | $20.42 | 2023 | |
| Phathom Pharmaceuticals, INC. | $16.21 | 2024 | Voquezna |
| Bayer Healthcare Pharmaceuticals INC. | $14.91 | 2025 | |
| Lilly USA, LLC | $13.63 | 2024 | Mounjaro, Zepbound |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katie Roedl listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.